Study finds participants saw reduction in depressive symptoms as researchers welcome ‘promising’ results

A phase II clinical trial has found dimethyltryptamine (DMT), one of the psychoactive components traditionally used in the Amazonian psychedelic ritual ayahuasca, might be a promising therapy for depression.

The psychedelic pharmaceutical company Small Pharma (now Cybin UK) sponsored and designed the trial, which was led by Dr David Erritzoe, a psychiatrist and neuroscientist at Imperial College London. The results were published in Nature this month.